top of page
The Sage Group is attending Bio Partnering at JPM in
San Francisco from
January 12-15, 2026! Please click here to meet!
See Latest News!
GLOBAL LIFE SCIENCES DEALMAKERS: 30+ YEARS. 300+ CLIENTS & TRANSACTIONS. BILLIONS IN VALUE.
The Sage Group
Why Sage?
About
Track Record
Locations
Added Value
Sage Clients
Testimonials
SAGEIQ
Services
M & A
Licensing
Sage Global
Sage APAC
Sage China
Sage Japan
Sage India
Team
Meet Us!
News
Downloads
Contact
More
Use tab to navigate through the menu items.
Sage Group News
The Sage Group: 30 Years of Successful Bioscience Transactions
London and New York, September 1 2024 Â - The Sage Group ( www.sagehealthcare.com ), a leading global advisor in the bioscience sector,...
Coagulant’s CT-001 - An Opportunity To License A Novel Factor VIIa with Orphan Drug Designation for the Treatment of Severe Postpartum Hemorrhage (sPPH)
Our client, Coagulant Therapeutics Corporation (CTC), is developing a novel, patented (4 families due to expire 2041-2043 period)...
Partnering/Licensing Opportunity for Tecarfarin, a Phase 3-Ready Oral Anticoagulant for Patients with Certain Orphan Diseases
Cadrenal Therapeutics ( www.cadrenal.com ; NASDAQ: CVKD) is a public U.S. company focused on advancing the development and...
bottom of page
%20(2).jpg)
